Heart & blood pressure · District of Columbia
Heart and blood pressure studies in District of Columbia
30 studies have at least one recruiting site in District of Columbia. Cardiovascular studies cover high blood pressure, high cholesterol, heart failure, atrial fibrillation and coronary artery disease, among others.
30 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- Recruiting
Prevail Global Study
Medtronic Vascular
- Location
- Washington D.C., DC + 53 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
Novo Nordisk A/S
- Location
- Washington D.C., DC + 58 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Alnylam Pharmaceuticals
- Location
- Washington D.C., DC + 40 other US sites
- Eligibility basics
- Ages 18–85
- RecruitingPhase 2
Transition to KPL-387 Monotherapy Dosing & Administration Study
Kiniksa Pharmaceuticals International, plc
- Location
- Washington D.C., DC + 20 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 2
A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)
AllRock Bio, Inc.
- Location
- Washington D.C., DC + 10 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 2/Phase 3
A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)
Merck Sharp & Dohme LLC
- Location
- Washington D.C., DC + 7 other US sites
- Eligibility basics
- Ages 6–17
- Recruiting
Zenith® Fenestrated+ Clinical Study
Cook Research Incorporated
- Location
- Washington D.C., DC + 29 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart Failure
Boston Scientific Corporation
- Location
- Washington D.C., DC + 39 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2/Phase 3
A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy
Kardigan, Inc.
- Location
- Washington D.C., DC + 26 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II
Shockwave Medical, Inc.
- Location
- Washington D.C., DC + 66 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
AstraZeneca
- Location
- Washington D.C., DC + 104 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.
Medtronic Cardiovascular
- Location
- Washington D.C., DC + 68 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold (RMS) System in Subjects With Coronary Artery Lesions
Teleflex
- Location
- Washington D.C., DC + 1 other US site
- Eligibility basics
- Ages 18–80
- RecruitingPhase 2/Phase 3
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
Merck Sharp & Dohme LLC
- Location
- Washington D.C., DC + 19 other US sites
- Eligibility basics
- Ages 1 mo–17
- RecruitingPhase 3
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
Eidos Therapeutics, a BridgeBio company
- Location
- Washington D.C., DC + 39 other US sites
- Eligibility basics
- Ages 18–75
- Recruiting
FORWARD CAD IDE Study
Shockwave Medical, Inc.
- Location
- Washington D.C., DC + 27 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
Immunovant Sciences GmbH
- Location
- Washington D.C., DC + 47 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia
Novartis Pharmaceuticals
- Location
- Washington D.C., DC + 3 other US sites
- Eligibility basics
- Ages 2–11
- RecruitingPhase 3
Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS
DalCor Pharmaceuticals
- Location
- Washington D.C., DC + 112 other US sites
- Eligibility basics
- Ages 45+
- Recruiting
Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure
Abbott Medical Devices
- Location
- Washington D.C., DC + 56 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy
Imbria Pharmaceuticals, Inc.
- Location
- Washington D.C., DC + 19 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia
Novartis Pharmaceuticals
- Location
- Washington D.C., DC + 6 other US sites
- Eligibility basics
- Ages 6–11
- RecruitingPhase 2
Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)
Merck Sharp & Dohme LLC
- Location
- Washington D.C., DC + 8 other US sites
- Eligibility basics
- Ages 1–17
- RecruitingPhase 3
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
Intellia Therapeutics
- Location
- Washington D.C., DC + 36 other US sites
- Eligibility basics
- Ages 18–90
Who these studies look for
Many require a diagnosis or specific lab values such as LDL cholesterol or blood pressure readings, and exclude recent heart events.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.
Questions
Do heart studies include healthy people?
Some do, especially early-phase studies and those measuring heart effects of new medicines. Check whether a listing says it accepts healthy volunteers.